Back to Dashboard








10x Genomics, Inc. (TXG)
Real-time intraday values
Market Overview
From:
To:
TXG Intraday
No data available
SymbolTXG
IPO DateSep 12, 2019
CEODr. Serge Saxonov Ph.D.
Full Time Employees1.2k
SectorHealthcare
IndustryHealth Information Services
CountryUnited States
ExchangeNasdaqGS
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | +1.68% | +0.54 US$ |
| 5 Days | +12.77% | +3.71 US$ |
| 1 Month | +54.53% | +11.56 US$ |
| 6 Months | +108.00% | +17.01 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of TXG...
Key Statistics
Market Cap
4.16B
P/E Ratio
N/A
Div Yield
N/A
52W High
$35.65
52W Low
$10.38
Analyst Consensus
ConsensusBuy
Bullish637.5%
Neutral1062.5%
Bearish00.0%
52W Analyst Price Targets
Min Target
$20.00
$20.00
Max Target
$32.00
$32.00
Current$32.76
Avg Target$25.77
Analyst Recommendations
Target Price:$25.77($20.00 - $32.00)
Community Thoughts
Share your analysis and sentiment on TXG
Join the community to share your analysis
Latest News for TXG
Cathie Wood Cleans House: Another Day Of Heavy Sales
Investor's Business Daily•Jun 16, 2026, 01:10 PM
X-Energy (XE) Powers 13.5% as Cathie Wood Gobbles More Stake
Insider Monkey•Jun 16, 2026, 02:34 AM
Cathie Wood Buys $444 Million in SpaceX, Dumps Tesla and AMD
GuruFocus.com•Jun 15, 2026, 06:48 PM
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities
Zacks•Jun 10, 2026, 05:04 PM
3 Small-Cap Stocks with Questionable Fundamentals
StockStory•Jun 11, 2026, 12:09 PM
Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge?
Simply Wall St.•Jun 10, 2026, 07:14 AM
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Zacks•Jun 10, 2026, 03:30 PM
10x Genomics Acquires Proteomics Specialist Proteintech Genomics
MT Newswires•Jun 9, 2026, 01:32 PM
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group
PR Newswire•Jun 9, 2026, 01:00 PM
Cathie Wood buys $8.7 million of tumbling semiconductor stock
TheStreet•Jun 8, 2026, 03:33 AM